Back to top

BTIG Keeps Their Buy Rating on Adaptive Biotechnologies (ADPT)

In a report released yesterday, Mark Massaro from BTIG reiterated a Buy rating on Adaptive Biotechnologies, with a price target of $24.00. The comp...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Adaptive Biotechnologies Corporation (ADPT)